Always intended for oncology as “intelligent” bullets capable of reaching the target directly, monoclonal antibodies are today the main protagonists in the fight against Covid-19. In fact, an important news is in fact at this time: Ema, the European Medicines Agency, has given a favorable opinion to an anti-Covid monoclonal antibody from Eli Lilly & Company. The antibody is called bamlanivimab, alone and in combination with etesevimab. Indeed, the company reports that EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab given together with etesevimab. The opinion suggests that bamlanivimab alone and bamlanivimab given together with etesevimab can be used for the treatment of Covid-19 in patients 12 years of age and older who do not require supplemental oxygen and who are at high risk of progressing to severe COVID-19. Data from the results of phase two and three of the study named Blaze-1 of Lilly showed that bamlanivimab alone reduces the viral load, symptoms and even hospitalizations for Covid-19 by about 70%, and that bamlanivimab and etesevimab together reduced the risk of Covid-19 hospitalizations and death by 70%. in high-risk non-hospitalized patients with mild to moderate Covid-19.
The news marks a huge step forward in the global fight against Covid-19. Lilly’s president and CEO, David A. Ricks, reiterated the company’s ongoing commitment to fighting the virus: “Lilly is proud that hundreds of thousands of patients around the world have already received treatment with our antibody therapy and we will continue to deliver on our commitment to help high-risk patients who could benefit as the world works to combat this pandemic.“.